Evaluating prognostic factors for submassive pulmonary embolism to guide invasive therapy decisions at the Centre Hospitalier Universitaire de Sherbrooke
Canadian Journal of General Internal Medicine · 01.06.2026 · 21 (2) · 135-142
DOI: 10.3138/cjgim.2025.0060 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of General Internal Medicine, erschienen am 01.06.2026. Verfasst von Charles St-Arnaud und 3 weiteren Autor:innen. Die Arbeit nennt 17 Literaturangaben.
Abstract (Originalsprache)
Introduction
The role of invasive strategies such as catheter-directed thrombectomy in high-risk submassive pulmonary embolism remains uncertain, as pivotal trials have relied on surrogate end points. This study evaluated outcomes among patients with high-risk submassive pulmonary embolism treated with anticoagulation alone at a single institution and compared them with published interventional cohorts.
Methods
A retrospective cohort study was conducted of adults admitted to the Centre Hospitalier Universitaire de Sherbrooke between 2018 and 2023 with confirmed pulmonary embolism, hemodynamic stability, and CT evidence of right ventricular strain (RV/LV > 0.9). Patients who initially received thrombolysis or catheter-based intervention were excluded. The primary outcome was major adverse events within 30 days, defined as a composite of death, hemodynamic or respiratory decompensation, or major bleeding.
Results
Eighty-eight patients were included (mean age, 68.3 ± 11.7 years; 47.7% female; 69.3% with a simplified Pulmonary Embolism Severity Index score ≥ 1). Within 30 days, 2 patients (2.3%; 95% CI, 0.3%–8.0%) experienced major adverse events, consisting of hemodynamic decompensation ( n = 2), including 1 in-hospital death. No major bleeding or recurrent pulmonary embolism occurred. Prognostic markers, including the right ventricular-to-left ventricular ratio, troponin level, and simplified Pulmonary Embolism Severity Index score, were not significantly associated with outcomes. Results were comparable to those of interventional trials despite the study cohort being older and at higher risk.
Discussion
Anticoagulation alone resulted in few adverse events and outcomes comparable to those reported in invasive thromboaspiration trials. Routine mechanical intervention may not be required for most patients with high-risk submassive pulmonary embolism. Future work should refine risk stratification, particularly for patients with cardiopulmonary comorbidities, who may represent a subgroup at greater risk.
Zitieren
APA
St-Arnaud, C., Gouin, B., Malick, M., & Saurel, J. (2026). Evaluating prognostic factors for submassive pulmonary embolism to guide invasive therapy decisions at the Centre Hospitalier Universitaire de Sherbrooke. Canadian Journal of General Internal Medicine, 21(2), 135-142. https://doi.org/10.3138/cjgim.2025.0060
Vancouver
St-Arnaud C, Gouin B, Malick M, Saurel J. Evaluating prognostic factors for submassive pulmonary embolism to guide invasive therapy decisions at the Centre Hospitalier Universitaire de Sherbrooke. Canadian Journal of General Internal Medicine. 2026;21(2):135-142. doi:10.3138/cjgim.2025.0060
BibTeX
@article{StArnaud2026,
author = {St-Arnaud, Charles and Gouin, Bobby and Malick, Mandy and Saurel, Justin},
title = {Evaluating prognostic factors for submassive pulmonary embolism to guide invasive therapy decisions at the Centre Hospitalier Universitaire de Sherbrooke},
journal = {Canadian Journal of General Internal Medicine},
year = {2026},
volume = {21},
number = {2},
pages = {135--142},
doi = {10.3138/cjgim.2025.0060}
}
EUVIMED